In order to strengthen its rare disease portfolio, Immedica has agreed to acquire Marinus Pharmaceuticals for approximately US$151 M. Through the deal, Immedica will gain access to Marinus’ lead asset, Ztalmy® (ganaxolone), a neuroactive steroid for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). This acquisition will enhance and complement Immedica's growth in North America, providing an immediate revenue-generating rare disease product in the US with the potential for additional geography expansion worldwide.